Psoriasis
What is
Psoriasis?
Psoriasis is an inflammatory skin
condition. There are five types, each with unique signs and
symptoms. Between 10% and 30% of people who develop psoriasis get a
related form of arthritis called “psoriatic arthritis,” which causes
inflammation of the joints.
Plaque psoriasis is the
most common type of psoriasis. About 80% of people who develop
psoriasis have plaque psoriasis, which appears as patches of raised,
reddish skin covered by silvery-white scale. These patches, or
plaques, frequently form on the elbows, knees, lower back,
and
scalp. However, the plaques can occur anywhere on the body.
The other types are guttate psoriasis (small, red
spots on the skin),
pustular psoriasis (white pustules surrounded by red skin), inverse psoriasis (smooth, red
lesions form in skin folds), and erythrodermic psoriasis
(widespread redness, severe itching, and pain).
Regardless of type, psoriasis usually
causes discomfort. The skin often itches, and it may crack and
bleed. In severe cases, the itching and discomfort may keep a person
awake at night, and the pain can make everyday tasks difficult.
Psoriasis is a chronic, meaning
lifelong, condition because there is currently no cure. People often
experience flares and remissions throughout their life. Controlling
the signs and symptoms typically requires lifelong therapy.
Treatment depends on the severity and
type of psoriasis. Some psoriasis is so mild that the person is
unaware of the condition. A few develop such severe psoriasis that
lesions cover most of the body and hospitalization is required.
These represent the extremes. Most cases of psoriasis fall somewhere
in between.
Who Gets Psoriasis
More than 4.5 million adults in the United States have been
diagnosed with psoriasis, and approximately 150,000 new cases are
diagnosed each year. An estimated 20% have moderate to severe
psoriasis.
Psoriasis occurs about equally in males
and females. Recent studies show that there may be an ethnic link.
It seems that psoriasis is most common in Caucasians and slightly
less common in African Americans. Worldwide, psoriasis is most
common in Scandinavia and other parts of northern Europe. It appears
to be far less common among Asians and is rare in Native Americans.
There also is a genetic component
associated with psoriasis. Approximately one-third of people who
develop psoriasis have at least one family member with the
condition.
Research shows that the signs and
symptoms of psoriasis usually appear between 15 and 35 years of age.
About 75% develop psoriasis before age 40. However, it is possible
to develop psoriasis at any age. After age 40, a peak onset period
occurs between 50 and 60 years of age.
About 1 in 10 people develop psoriasis
during childhood, and psoriasis can begin in infancy. The earlier
the psoriasis appears, the more likely it is to be widespread and
recurrent.
Psoriatic arthritis develops in roughly
one million people across the United States, and 5% to 10%
experience some disability. Psoriatic arthritis usually first
appears between 30 and 50 years of age — often months to years after
skin lesions first occur. However, not everyone who develops
psoriatic arthritis has psoriasis. About 30% of people who get
psoriatic arthritis never develop the skin condition.
Causes
Psoriasis may be one of the oldest recorded skin conditions. It
was probably first described around 35 AD. Some evidence indicates
an even earlier date. Yet, until recently, little was known about
psoriasis.
While scientists still do not fully
know what causes psoriasis, research has significantly advanced our
understanding. One important breakthrough began with the discovery
that kidney-transplant recipients who had psoriasis experienced
clearing when taking cyclosporine. Since cyclosporine is a potent
immunosuppressive medication, this indicates that the immune system
is involved.
Immune Mediated. Researchers now
believe that psoriasis is an immune-mediated condition. This means
the condition is caused by faulty signals in the body’s immune
system. It is believed that psoriasis develops when the immune
system tells the body to over-react and accelerate the growth of
skin cells. Normally, skin cells mature and are shed from the skin’s
surface every 28 to 30 days. When psoriasis develops, the skin cells
mature in 3 to 6 days and move to the skin surface. Instead of being
shed, the skin cells pile up, causing the visible lesions.
Genes. Researchers have
identified genes that cause psoriasis. These genes determine how a
person’s immune system reacts. These genes can cause psoriasis or
another immune-mediated condition, such as rheumatoid arthritis or
type 1 diabetes. The risk of developing psoriasis or another
immune-mediated condition, especially diabetes or Crohn’s disease,
increases when a close blood relative has psoriasis.
Family History. Some people who
have a family history of psoriasis never develop this condition.
Research indicates that a “trigger” is needed. Stress, skin
injuries, a strep infection, certain medications, and sunburn are
some of the known potential triggers. Medications that can trigger
psoriasis are anti-malarial drugs, beta-blockers (medication used to
treat high blood pressure and heart conditions), and lithium.
Dermatologists have seen psoriasis suddenly appear after a person
takes one of these medications, gets a strep infection, or
experiences another trigger.
Psoriasis research continues to
accelerate at a rapid pace and will continue to advance our
knowledge of what causes psoriasis.
Quality of Life
All types of psoriasis, ranging from mild to severe, can affect a
person’s quality of life. Living with this lifelong condition can be
physically and emotionally challenging.
Itching, soreness, and cracked and
bleeding skin are common. Nail psoriasis can be painful. Even the
simple act of squeezing a tube of toothpaste can hurt. One woman
described her psoriasis as feeling like “a bad sunburn that won’t go
away.”
Several studies have shown that people
often feel frustrated. In some cases, psoriasis limits activities
and makes it difficult to perform job responsibilities. The National
Psoriasis Foundation reports that 56 million work hours are lost
each year by those who have psoriasis. Additionally, a survey
conducted by the National Psoriasis Foundation in 2002 indicates
that 26% of people living with moderate to severe psoriasis have
been forced to change or discontinue their normal daily activities.
Studies also have shown that stress,
anxiety, loneliness, and low self-esteem are part of daily life for
people living with psoriasis. One study found that thoughts of
suicide are three times higher for psoriatics than the general
population.
Embarrassment is another common
feeling. Imagine getting your hair cut and noticing that the stylist
or barber is visibly uncomfortable. What if you extended your hand
to someone and the person recoiled? How would you feel if you spent
most of your life trying to hide your skin?
Treatment Advances Improve Outlook
With the emergence of several new therapies, including the biologic
agents, more people are experiencing substantial improvements and
reporting a greatly improved quality of life.
References:
American Academy of Dermatology. “American Academy of
Dermatology’s Psoriasis Public Awareness Campaign Provides Latest
Information About this Skin Condition.” Available at:
http://www.newswire1.net/NW2004/C_AAD_CH/111504/index.html.
Accessed April 26, 2005.
American Academy of Dermatology. Psoriasis. Available at:
http://www.aad.org/public/Publications/pamphlets/Psoriasis.htm.
Accessed April 26, 2005.
Bowcock, A et al. “Genetics of psoriasis: The potential impact on
new therapies.” Journal of the American Academy of Dermatology.
2003 August;49(2):S51-6.
Gupta MA et al. “Suicidal ideation in psoriasis.” International
Journal of Dermatology. 1993 March;32(3):188-90
Holsinger, L. “A battle with my skin.” Journal of the American
Academy of Dermatology. 2004 July;51(1)S41-42.
Hurley, HJ. “Papulosquamous Eruptions and Exfoliative Dermatitis” in
Dermatology. Philadelphia, PA: W.B. Saunders Company; 1975.
Lebwohl, M. “Innovations in the treatment of psoriasis.” Journal
of the American Academy of Dermatology. 2004 July;51(1)S40-41.
The Lewin Group, Inc. The Burden of Skin Diseases. Prepared
for the Society for Investigative Dermatology and the American
Academy of Dermatology Association. 2005. Available at:
http://www.newswire1.net/NW2005/C_AAD_CH/AAD3001388_040605/assets/
downloads/printfriendlyskin.pdf. Accessed June 21, 2005.
National Psoriasis Foundation. Psoriasis and Psoriatic Arthritis:
Treatment Guide for the Health Insurance Industry. 2004.
|